Dr Simon Opher

Dr Simon Opher

Labour — Stroud

Speaking in the House of Commons on 17 November 2026

Debate

Medicines and Healthcare Products Regulatory Agency

Contribution

Good morning, Sir John. I thank the right hon. Member for Tatton (Esther McVey) for securing the debate. Although there have been serious allegations about the MHRA and vaccines, I want to commend the enormous number of NHS staff who delivered the covid vaccine programme, which saved hundreds of thousands of lives—particularly those of older people. I do not want them to be denigrated by our debate. I want to focus on the role of the MHRA with regard to antidepressants. I am the chair of the beyond pills all-party parliamentary group, and I chair our expert working group on antidepressant prescribing strategy. In particular, we want to highlight the problems associated with prescribed dependence-forming drugs such as antidepressants and the relevance of non-drug alternatives, such as social prescribing, talking therapies and access to nature. Although antidepressants may help some people, overmedicalisation is a key concern. According to the latest figures, about 9.1 million people in England alone are on antidepressants and, shockingly, 187,000 patients under 19 were prescribed antidepressants in the last year. I am a GP with 30 years’ experience, and I specialise in mental health. I know that a significant number of patients are prescribed antidepressants when in fact they are feeling completely normal emotions in response to difficult life situations. They are not suffering from a medical condition and do not, in the main, need drug treatment. The rising number of antidepressants prescribed brings up the issue of informed consent. Patients must be given clear information about the benefits and risks of antidepressants so that they can make a truly informed decision with their doctor about whether they want to take the drugs. That is where the MHRA comes in. We want to work constructively with the MHRA. I commend it on its recent initiatives recognising the need to strengthen the communication of risk around suicidality and sexual dysfunction with antidepressants. It should support the process of shared decision making between doctors and patients. We also welcome the MHRA’s patient and public involvement and engagement plan, published on 5 November, which will take into account the lived experience of patients and carers in decision making. However, the MHRA needs to do that in other areas too, and there are still areas where we would like the risks to be communicated better, including akathisia—a distressing condition of such intense mental and physical disorder that people often say they want to take their own lives. Another key issue is that patients are invariably not informed that they have an average chance of only one in eight that antidepressants will benefit their mental health.

More from Dr Simon Opher

Other recent Hansard contributions by the same speaker.

About Hansard

Hansard is the official verbatim record of proceedings in the UK Parliament. Every word spoken in the Commons and Lords is recorded and published — this page is a single contribution from that record.

For Dr Simon Opher's full parliamentary record including voting history, expenses and all other contributions, see the Dr Simon Opher report card.